Literature DB >> 10479304

Lobeline: structure-affinity investigation of nicotinic acetylcholinergic receptor binding.

D Flammia1, M Dukat, M I Damaj, B Martin, R A Glennon.   

Abstract

(-)Lobeline (1) and (-)nicotine (2) bind at neuronal nicotinic cholinergic (nACh) receptors with high affinity (K(i) = 4 and 2 nM, respectively). Previous attempts to determine whether lobeline fits the currently accepted nicotinic pharmacophore model have led to suggestions that the carbonyl function, rather than the hydroxyl group, is a major contributor to binding. Interestingly, however, it has never been empirically demonstrated that either oxygen function is actually required for interaction with the receptor. In the present investigation we systematically examined a number of abbreviated analogues of lobeline and found that removal of either one or both oxygen functions reduces the affinity of lobeline by at least 25-fold; furthermore, oxidation of the (-)lobeline hydroxyl group (to afford lobelanine) or reduction of the carbonyl group (to afford lobelanidine) also resulted in decreased affinity. Although it is likely that both oxygen functions contribute to the high affinity of (-)lobeline at nACh receptors, it is concluded that the presence of both oxygen functions is not a requirement for binding; that is, replacement of the (-)lobeline hydroxyl group with a chloro group had no effect on affinity. Another finding of the present investigation is that removal of either one or both oxygen functions of lobeline results in compounds that retain the analgesic activity and potency of (-)lobeline, indicating that there is no direct relationship between neuronal nicotinic cholinergic (primarily alpha(4)beta(2) type) receptor affinity and spinal analgesia as measured in the tail-flick assay.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479304     DOI: 10.1021/jm990286m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.

Authors:  Vidya Narayanaswami; Sucharita S Somkuwar; David B Horton; Lisa A Cassis; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

Review 2.  Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Authors:  Peter A Crooks; Guangrong Zheng; Ashish P Vartak; John P Culver; Fang Zheng; David B Horton; Linda P Dwoskin
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  The twin drug approach for novel nicotinic acetylcholine receptor ligands.

Authors:  Isabelle Tomassoli; Daniela Gündisch
Journal:  Bioorg Med Chem       Date:  2015-06-20       Impact factor: 3.641

4.  meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Authors:  David B Horton; Kiran B Siripurapu; Seth D Norrholm; John P Culver; Marhaba Hojahmat; Joshua S Beckmann; Steven B Harrod; Agripina G Deaciuc; Michael T Bardo; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

5.  DNA damage and oxidative stress induced by seizures are decreased by anticonvulsant and neuroprotective effects of lobeline, a candidate to treat alcoholism.

Authors:  Liana Dantas da Costa E Silva; Patrícia Pereira; Gabriela Gregory Regner; Fernanda Brião Menezes Boaretto; Cleonice Hoffmann; Pricila Pflüger; Lucas Lima da Silva; Luiza Reinhardt Steffens; Ana Moira Morás; Dinara Jaqueline Moura; Jaqueline Nascimento Picada
Journal:  Metab Brain Dis       Date:  2017-10-14       Impact factor: 3.584

Review 6.  The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Authors:  Justin R Nickell; Kiran B Siripurapu; Ashish Vartak; Peter A Crooks; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

7.  Synthesis of Lobeline, Lobelane and their Analogues. A Review.

Authors:  Guangrong Zheng; Peter A Crooks
Journal:  Org Prep Proced Int       Date:  2015-08-17       Impact factor: 1.628

8.  Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Seth D Norrholm; Peter A Crooks
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

Review 9.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

10.  Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).

Authors:  Ashish P Vartak; Justin R Nickell; Jaturaporn Chagkutip; Linda P Dwoskin; Peter A Crooks
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.